Arcalyst (rilonacept) Global Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Arcalyst (rilonacept) is a prescription medication categorized as an interleukin-1 (IL-1) inhibitor. It is used to treat specific inflammatory conditions that result from excessive production of interleukin-1, a protein central to the body's inflammatory response. Rilonacept acts by binding to interleukin-1 alpha and beta, preventing their interaction with cellular receptors, which reduces inflammation and helps relieve symptoms linked to the underlying disorders.

The main forms of Arcalyst (rilonacept) include lyophilized and liquid formulations. Lyophilized Arcalyst is a freeze-dried version of rilonacept that is reconstituted before administration. The clinical indications include cryopyrin-associated periodic syndromes (CAPS), deficiency of interleukin-1 receptor antagonist (DIRA), and other conditions. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies and is used by both adult and pediatric patients.

Tariffs have moderately influenced the arcalyst market by increasing costs for imported biologic ingredients and injectable formulation components. These impacts are most evident in hospital and specialty pharmacy distribution channels across north america and europe. Higher tariffs have contributed to pricing pressures for orphan biologic therapies. At the same time, tariffs are encouraging localized biologic manufacturing and supply chain diversification. This supports long term treatment availability and market stability.

The arcalyst (rilonacept) market research report is one of a series of new reports from The Business Research Company that provides arcalyst (rilonacept) market statistics, including arcalyst (rilonacept) industry global market size, regional shares, competitors with a arcalyst (rilonacept) market share, detailed arcalyst (rilonacept) market segments, market trends and opportunities, and any further data you may need to thrive in the arcalyst (rilonacept) industry. This arcalyst (rilonacept) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The arcalyst (rilonacept) market size has grown strongly in recent years. It will grow from $0.24 million in 2025 to $0.26 million in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to identification of il 1 driven diseases, limited alternatives for rare inflammatory conditions, strong clinical outcomes with rilonacept, regulatory approvals for orphan indications, specialist adoption of biologic therapies.

The arcalyst (rilonacept) market size is expected to see strong growth in the next few years. It will grow to $0.33 million in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to growing diagnosis of autoinflammatory syndromes, expansion into additional indications, improved genetic screening, increased biologic therapy accessibility, rising investment in rare disease treatments. Major trends in the forecast period include rising adoption of il 1 blocking therapies, growing use in rare autoinflammatory disorders, expansion of long term inflammation control treatments, increased focus on targeted cytokine inhibition, improved disease management for chronic inflammatory conditions.

The growing demand for personalized medicines is expected to propel the growth of the Arcalyst (rilonacept) market going forward. Personalized medicine is a healthcare approach that customizes treatment and clinical decisions based on an individual's genetic makeup, environment, and lifestyle. The demand for personalized medicine is increasing due to its ability to enhance treatment efficacy, minimize adverse effects, and address patient-specific differences in disease progression and drug response. As personalized medicine gains wider adoption, improved diagnostic tools and heightened awareness are enabling better identification of rare and genetically driven conditions. This, in turn, leads to a higher number of patients being diagnosed with conditions that can be treated with Arcalyst, thereby increasing demand for the drug. For instance, in February 2024, according to a report published by the Personalized Medicine Coalition (PMC), a US-based non-profit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six approvals in 2022. Additionally, in February 2023, PMC reported that the FDA approved 12 new personalized medicines in 2022, marking the eighth consecutive year in which personalized medicines accounted for at least one-quarter of all new drug approvals. Therefore, the rising demand for personalized medicine is driving the growth of the Arcalyst (rilonacept) market.

Major companies operating in the Arcalyst (rilonacept) market are concentrating on expanding indications, such as the use of interleukin-1 (IL-1) trap therapy for recurrent pericarditis, to strengthen their competitive position. Interleukin-1 trap therapy works by blocking excessive IL-1 proteins, thereby reducing harmful inflammation in the body. For instance, in May 2024, Kiniksa Pharmaceuticals, a US-based biopharmaceutical company, received FDA approval for Arcalyst in the treatment of recurrent pericarditis. The approval includes features such as weekly subcutaneous dosing, dual IL-1a and IL-1B inhibition, and a favorable long-term safety profile. This indication expansion significantly broadens Arcalyst's target patient population beyond its initial use in Cryopyrin-Associated Periodic Syndromes (CAPS), although wider utilization may also increase exposure to competition, long-term safety evaluation, and payer scrutiny.

In August 2023, Fairmount Funds Management LLC, a South Philadelphia-based investment firm, acquired a stake in Kiniksa Pharmaceuticals for an undisclosed amount. This investment aligns with Fairmount's long-term strategy of generating value within the biotechnology sector. Kiniksa Pharmaceuticals is a Bermuda-based company that manufactures Arcalyst (rilonacept).

Major companies operating in the arcalyst (rilonacept) market are Regeneron Pharmaceuticals Inc., Kiniksa Pharmaceuticals Ltd.

North America was the largest region in the arcalyst (rilonacept) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the arcalyst (rilonacept) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the arcalyst (rilonacept) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The arcalyst (rilonacept) market consists of monoclonal antibodies, anti-inflammatory drugs, rare disease drugs and other related products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Arcalyst (rilonacept) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses arcalyst (rilonacept) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for arcalyst (rilonacept) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The arcalyst (rilonacept) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Lyophilized; Liquid
• 2) By Indication: Cryopyrin-Associated Periodic Syndromes (CAPS); Deficiency Of Interleukin-1 Receptor Antagonist (DIRA); Other Indications
• 3) By Distribution Channels: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By End User: Adult Patients; Pediatric Patients
• Companies Mentioned: Regeneron Pharmaceuticals Inc.; Kiniksa Pharmaceuticals Ltd.
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.